Dr. Bakal is the Program Director for Provincial Research Data Services at Alberta Health Services, which operates the Alberta Strategy for Patient Oriented Research (SPOR) data platform. He also leads the Health Service Statistical and Analytics Methods teams. Over 10 years, he has worked with health services data, including randomized clinical trials. He completed his PhD jointly through the Department of Mathematics and Statistics and the School of Physical Health and Education at Queen’s University. His work includes methodological contributions and analyses supporting international studies spanning business strategy, ophthalmology, cardiology, and geriatric medicine, as well as analyses of kinematic data, through peer-reviewed publications and conference presentations. Current interests include developing statistical methodology for time-to-event data and building classification tools to support patient decision-making processes. Daniel Kim works in Radiation Oncology at the Inova Schar Cancer Institute, Fairfax, VA, USA. David E. Wazer, MD, is Professor and Chairman of the Department of Radiation Oncology at Brown University. He is radiation oncologist-in-chief at Rhode Island Hospital, the Miriam Hospital, Newport Hospital, and Women and Infants Hospital. He serves as Director of the Lifespan Cancer Institute. Dr. Wazer’s current areas of clinical research include the study of the efficacy, toxicity, and cost/utility analysis of image-guided radiation therapy, proton beam radiotherapy, partial breast irradiation, and brachytherapy. He is actively involved in the development of clinical trials for cancers of the breast, skin, GI tract, and lung. He is also actively engaged in multiple initiatives to promote and advance oncology care in the developing world. Dr Adam E. M. Eltorai, MD, PhD completed his graduate studies in Biomedical Engineering and Biotechnology along with his medical degree from Brown University. His work has spanned the translational spectrum with a focus on medical technology innovation and development. Dr. Eltorai has published numerous articles and books.

• INTRODUCTION 1. Introduction; 2. Translational Process; 3. Scientific Method; 4. Basic ResearchPRE-CLINCIAL: DISCOVERY AND DEVELOPMENT 5. Overview of Preclinical Research; 6. What problem are you Solving?; 7. Types of Interventions; 8. Drug discovery; 9. Drug Testing; 10. Device Discovery and Prototyping; 11. Device Testing; 12. Diagnostic Discovery; 13. Diagnostic Testing; 14. Procedural Technique Development; 15. Behavioral Intervention; 16. Artificial IntelligenceCLINICAL: FUNDAMENTALS 17. Introduction to clinical research: What is it? Why is it needed?; 18. The question: Types of research questions and how to develop them; 19. Study population: Who and why them?; 20. Outcome measurements: What data is being collected and why?; 21. Optimizing the Question: Balancing Significance and Feasibility; 22. Statistical Efficiency in Study DesignSTATISTICAL PRINCIPLES 23. Basic statistical principles; 24. Distributions; 25. Hypotheses and error types; 26. Power; 27. Regression; 28. Continuous variable analyses: t-test, Man Whitney, Wilcoxin rank; 29. Categorical variable analyses: Chi-square, fisher exact, Mantel hanzel; 30. Analysis of variance; 31. Correlation; 32. Biases; 33. Basic science statistics; 34. Sample Size; 35. Statistical SoftwareCLINICAL: STUDY TYPES 36. Design principles: Hierarchy of study types; 37. Case series: Design, measures, classic example; 38. Case-control study: Design, measures, classic example; 39. Cohort study: Design, measures, classic example; 40. Cross-section study: Design, measures, classic example; 41. Longitudinal Study: Design, Measures, Classic Example; 42. Meta-analysis: Design, measures, real-world examples; 43. Cost-effectiveness study: Design, measures, classic example; 44. Diagnostic test evaluation: Design, measures, classic example; 45. Reliability study: Design, measures, classic example; 46. Database studies; 47. Surveys and questionnaires: Design, measures, classic example; 48. Qualitative methods and mixed methods; 49. Visual analytics: design, measures, classic exampleCLINICAL TRIALS 50. Randomized control: Design, measures, classic example; 51. Nonrandomized control: Design, measures, classic example; 52. Historical control: Design, measures, classic example; 53. Cross-over: Design, measures, classic example; 54. Factorial design: Design, measures, classic example; 55. Large, pragmatic: Design, measures, classic example; 56. Equivalence and noninferiority: Design, measures, classic example; 57. Adaptive: Design, measures, classic example; 58. Randomization: Fixed or adaptive procedures; 59. Blinding: Who and how?; 60. Multicenter considerations; 61. Phase 0 Trials: Window of Opportunity; 62. Registries; 63. Phases of Clinical Trials; 64. IDEAL FrameworkCLINICAL: PREPARATION 65. Patient Perspectives; 66. Ethics and review boards; 67. Regulatory considerations for new drugs and devices; 68. Funding approaches; 69. Conflicts of Interest; 70. Subject recruitment; 71. Data management; 72. Quality control; 73. Special Populations; 74. Report Forms: Harm and Quality of Life; 75. Subject adherence; 76. Survival analysisREGULATORY BASICS 77. FDA overview; 78. IND; 79. New drug application; 80. Devices; 81. Radiation-Emitting Electronic Products; 82. Orphan Drugs; 83. Biologics; 84. Combination Products; 85. CMC and GxP; 86. Post-Market Drug Safety Monitoring; 87. Post-Market Device Safety MonitoringCLINICAL IMPLEMENTATION 88. Implementation Research; 89. Design and Analysis; 90. Mixed-Methods Research; 91. Guideline Development; 92. Cooperative Group Research; 93. Digital HealthPUBLIC HEALTH 94. Public Health; 95. Epidemiology; 96. Factors; 97. Good Questions; 98. Population- and Environmental-Specific Considerations; 99. Law, Policy, and Ethics; 100. Public Health Institutions and Systems; 101. DEI (Diversity, equity, inclusion)PRACTICAL RESOURCES102. Ethics in Scientific Publishing; 103. Presenting Data; 104. Manuscript Preparation; 105. Promoting Research; 106. Social Media; 107. Quality Improvement; 108. Education to translate research into practice; 109. Team Science and Building a Team; 110. Patent Basics; 111. Venture Pathways; 112. SBIR/STTR; 113. Sample Forms and Templates

Select Guide Rating

Dr. Bakal is the Program Director for Provincial Research Data Services at Alberta Health Services, which operates the Alberta Strategy for Patient Oriented Research (SPOR) data platform. He also leads the Health Service Statistical and Analytics Methods teams. Over 10 years, he has worked with health services data, including randomized clinical trials. He completed his PhD jointly through the Department of Mathematics and Statistics and the School of Physical Health and Education at Queen’s University. His work includes methodological contributions and analyses supporting international studies spanning business strategy, ophthalmology, cardiology, and geriatric medicine, as well as analyses of kinematic data, through peer-reviewed publications and conference presentations. Current interests include developing statistical methodology for time-to-event data and building classification tools to support patient decision-making processes. Daniel Kim works in Radiation Oncology at the Inova Schar Cancer Institute, Fairfax, VA, USA. David E. Wazer, MD, is Professor and Chairman of the Department of Radiation Oncology at Brown University. He is radiation oncologist-in-chief at Rhode Island Hospital, the Miriam Hospital, Newport Hospital, and Women and Infants Hospital. He serves as Director of the Lifespan Cancer Institute. Dr. Wazer’s current areas of clinical research include the study of the efficacy, toxicity, and cost/utility analysis of image-guided radiation therapy, proton beam radiotherapy, partial breast irradiation, and brachytherapy. He is actively involved in the development of clinical trials for cancers of the breast, skin, GI tract, and lung. He is also actively engaged in multiple initiatives to promote and advance oncology care in the developing world. Dr Adam E. M. Eltorai, MD, PhD completed his graduate studies in Biomedical Engineering and Biotechnology along with his medical degree from Brown University. His work has spanned the translational spectrum with a focus on medical technology innovation and development. Dr. Eltorai has published numerous articles and books.

• INTRODUCTION 1. Introduction; 2. Translational Process; 3. Scientific Method; 4. Basic ResearchPRE-CLINCIAL: DISCOVERY AND DEVELOPMENT 5. Overview of Preclinical Research; 6. What problem are you Solving?; 7. Types of Interventions; 8. Drug discovery; 9. Drug Testing; 10. Device Discovery and Prototyping; 11. Device Testing; 12. Diagnostic Discovery; 13. Diagnostic Testing; 14. Procedural Technique Development; 15. Behavioral Intervention; 16. Artificial IntelligenceCLINICAL: FUNDAMENTALS 17. Introduction to clinical research: What is it? Why is it needed?; 18. The question: Types of research questions and how to develop them; 19. Study population: Who and why them?; 20. Outcome measurements: What data is being collected and why?; 21. Optimizing the Question: Balancing Significance and Feasibility; 22. Statistical Efficiency in Study DesignSTATISTICAL PRINCIPLES 23. Basic statistical principles; 24. Distributions; 25. Hypotheses and error types; 26. Power; 27. Regression; 28. Continuous variable analyses: t-test, Man Whitney, Wilcoxin rank; 29. Categorical variable analyses: Chi-square, fisher exact, Mantel hanzel; 30. Analysis of variance; 31. Correlation; 32. Biases; 33. Basic science statistics; 34. Sample Size; 35. Statistical SoftwareCLINICAL: STUDY TYPES 36. Design principles: Hierarchy of study types; 37. Case series: Design, measures, classic example; 38. Case-control study: Design, measures, classic example; 39. Cohort study: Design, measures, classic example; 40. Cross-section study: Design, measures, classic example; 41. Longitudinal Study: Design, Measures, Classic Example; 42. Meta-analysis: Design, measures, real-world examples; 43. Cost-effectiveness study: Design, measures, classic example; 44. Diagnostic test evaluation: Design, measures, classic example; 45. Reliability study: Design, measures, classic example; 46. Database studies; 47. Surveys and questionnaires: Design, measures, classic example; 48. Qualitative methods and mixed methods; 49. Visual analytics: design, measures, classic exampleCLINICAL TRIALS 50. Randomized control: Design, measures, classic example; 51. Nonrandomized control: Design, measures, classic example; 52. Historical control: Design, measures, classic example; 53. Cross-over: Design, measures, classic example; 54. Factorial design: Design, measures, classic example; 55. Large, pragmatic: Design, measures, classic example; 56. Equivalence and noninferiority: Design, measures, classic example; 57. Adaptive: Design, measures, classic example; 58. Randomization: Fixed or adaptive procedures; 59. Blinding: Who and how?; 60. Multicenter considerations; 61. Phase 0 Trials: Window of Opportunity; 62. Registries; 63. Phases of Clinical Trials; 64. IDEAL FrameworkCLINICAL: PREPARATION 65. Patient Perspectives; 66. Ethics and review boards; 67. Regulatory considerations for new drugs and devices; 68. Funding approaches; 69. Conflicts of Interest; 70. Subject recruitment; 71. Data management; 72. Quality control; 73. Special Populations; 74. Report Forms: Harm and Quality of Life; 75. Subject adherence; 76. Survival analysisREGULATORY BASICS 77. FDA overview; 78. IND; 79. New drug application; 80. Devices; 81. Radiation-Emitting Electronic Products; 82. Orphan Drugs; 83. Biologics; 84. Combination Products; 85. CMC and GxP; 86. Post-Market Drug Safety Monitoring; 87. Post-Market Device Safety MonitoringCLINICAL IMPLEMENTATION 88. Implementation Research; 89. Design and Analysis; 90. Mixed-Methods Research; 91. Guideline Development; 92. Cooperative Group Research; 93. Digital HealthPUBLIC HEALTH 94. Public Health; 95. Epidemiology; 96. Factors; 97. Good Questions; 98. Population- and Environmental-Specific Considerations; 99. Law, Policy, and Ethics; 100. Public Health Institutions and Systems; 101. DEI (Diversity, equity, inclusion)PRACTICAL RESOURCES102. Ethics in Scientific Publishing; 103. Presenting Data; 104. Manuscript Preparation; 105. Promoting Research; 106. Social Media; 107. Quality Improvement; 108. Education to translate research into practice; 109. Team Science and Building a Team; 110. Patent Basics; 111. Venture Pathways; 112. SBIR/STTR; 113. Sample Forms and Templates

Select Guide Rating

Dr. Bakal is the Program Director for Provincial Research Data Services at Alberta Health Services, which operates the Alberta Strategy for Patient Oriented Research (SPOR) data platform. He also leads the Health Service Statistical and Analytics Methods teams. Over 10 years, he has worked with health services data, including randomized clinical trials. He completed his PhD jointly through the Department of Mathematics and Statistics and the School of Physical Health and Education at Queen’s University. His work includes methodological contributions and analyses supporting international studies spanning business strategy, ophthalmology, cardiology, and geriatric medicine, as well as analyses of kinematic data, through peer-reviewed publications and conference presentations. Current interests include developing statistical methodology for time-to-event data and building classification tools to support patient decision-making processes. Daniel Kim works in Radiation Oncology at the Inova Schar Cancer Institute, Fairfax, VA, USA. David E. Wazer, MD, is Professor and Chairman of the Department of Radiation Oncology at Brown University. He is radiation oncologist-in-chief at Rhode Island Hospital, the Miriam Hospital, Newport Hospital, and Women and Infants Hospital. He serves as Director of the Lifespan Cancer Institute. Dr. Wazer’s current areas of clinical research include the study of the efficacy, toxicity, and cost/utility analysis of image-guided radiation therapy, proton beam radiotherapy, partial breast irradiation, and brachytherapy. He is actively involved in the development of clinical trials for cancers of the breast, skin, GI tract, and lung. He is also actively engaged in multiple initiatives to promote and advance oncology care in the developing world. Dr Adam E. M. Eltorai, MD, PhD completed his graduate studies in Biomedical Engineering and Biotechnology along with his medical degree from Brown University. His work has spanned the translational spectrum with a focus on medical technology innovation and development. Dr. Eltorai has published numerous articles and books.

• INTRODUCTION 1. Introduction; 2. Translational Process; 3. Scientific Method; 4. Basic ResearchPRE-CLINCIAL: DISCOVERY AND DEVELOPMENT 5. Overview of Preclinical Research; 6. What problem are you Solving?; 7. Types of Interventions; 8. Drug discovery; 9. Drug Testing; 10. Device Discovery and Prototyping; 11. Device Testing; 12. Diagnostic Discovery; 13. Diagnostic Testing; 14. Procedural Technique Development; 15. Behavioral Intervention; 16. Artificial IntelligenceCLINICAL: FUNDAMENTALS 17. Introduction to clinical research: What is it? Why is it needed?; 18. The question: Types of research questions and how to develop them; 19. Study population: Who and why them?; 20. Outcome measurements: What data is being collected and why?; 21. Optimizing the Question: Balancing Significance and Feasibility; 22. Statistical Efficiency in Study DesignSTATISTICAL PRINCIPLES 23. Basic statistical principles; 24. Distributions; 25. Hypotheses and error types; 26. Power; 27. Regression; 28. Continuous variable analyses: t-test, Man Whitney, Wilcoxin rank; 29. Categorical variable analyses: Chi-square, fisher exact, Mantel hanzel; 30. Analysis of variance; 31. Correlation; 32. Biases; 33. Basic science statistics; 34. Sample Size; 35. Statistical SoftwareCLINICAL: STUDY TYPES 36. Design principles: Hierarchy of study types; 37. Case series: Design, measures, classic example; 38. Case-control study: Design, measures, classic example; 39. Cohort study: Design, measures, classic example; 40. Cross-section study: Design, measures, classic example; 41. Longitudinal Study: Design, Measures, Classic Example; 42. Meta-analysis: Design, measures, real-world examples; 43. Cost-effectiveness study: Design, measures, classic example; 44. Diagnostic test evaluation: Design, measures, classic example; 45. Reliability study: Design, measures, classic example; 46. Database studies; 47. Surveys and questionnaires: Design, measures, classic example; 48. Qualitative methods and mixed methods; 49. Visual analytics: design, measures, classic exampleCLINICAL TRIALS 50. Randomized control: Design, measures, classic example; 51. Nonrandomized control: Design, measures, classic example; 52. Historical control: Design, measures, classic example; 53. Cross-over: Design, measures, classic example; 54. Factorial design: Design, measures, classic example; 55. Large, pragmatic: Design, measures, classic example; 56. Equivalence and noninferiority: Design, measures, classic example; 57. Adaptive: Design, measures, classic example; 58. Randomization: Fixed or adaptive procedures; 59. Blinding: Who and how?; 60. Multicenter considerations; 61. Phase 0 Trials: Window of Opportunity; 62. Registries; 63. Phases of Clinical Trials; 64. IDEAL FrameworkCLINICAL: PREPARATION 65. Patient Perspectives; 66. Ethics and review boards; 67. Regulatory considerations for new drugs and devices; 68. Funding approaches; 69. Conflicts of Interest; 70. Subject recruitment; 71. Data management; 72. Quality control; 73. Special Populations; 74. Report Forms: Harm and Quality of Life; 75. Subject adherence; 76. Survival analysisREGULATORY BASICS 77. FDA overview; 78. IND; 79. New drug application; 80. Devices; 81. Radiation-Emitting Electronic Products; 82. Orphan Drugs; 83. Biologics; 84. Combination Products; 85. CMC and GxP; 86. Post-Market Drug Safety Monitoring; 87. Post-Market Device Safety MonitoringCLINICAL IMPLEMENTATION 88. Implementation Research; 89. Design and Analysis; 90. Mixed-Methods Research; 91. Guideline Development; 92. Cooperative Group Research; 93. Digital HealthPUBLIC HEALTH 94. Public Health; 95. Epidemiology; 96. Factors; 97. Good Questions; 98. Population- and Environmental-Specific Considerations; 99. Law, Policy, and Ethics; 100. Public Health Institutions and Systems; 101. DEI (Diversity, equity, inclusion)PRACTICAL RESOURCES102. Ethics in Scientific Publishing; 103. Presenting Data; 104. Manuscript Preparation; 105. Promoting Research; 106. Social Media; 107. Quality Improvement; 108. Education to translate research into practice; 109. Team Science and Building a Team; 110. Patent Basics; 111. Venture Pathways; 112. SBIR/STTR; 113. Sample Forms and Templates

Select Guide Rating